help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stroh, T.
Right arrow Articles by Beaudet, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stroh, T.
Right arrow Articles by Beaudet, A.
Endocrinology Vol. 141, No. 1 354-365
Copyright © 2000 by The Endocrine Society


ARTICLES

Intracellular Dynamics of sst5 Receptors in Transfected COS-7 Cells: Maintenance of Cell Surface Receptors during Ligand-Induced Endocytosis1

Thomas Stroh, Alexander C. Jackson, Philippe Sarret, Claude Dal Farra, Jean-Pierre Vincent, Hans-Jürgen Kreienkamp, Jean Mazella and Alain Beaudet

Montreal Neurological Institute, McGill University (T.S., A.C.J., A.B.), Montréal, Québec, Canada H3A 2B4; Institut de Pharmacologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Université de Nice-Sophia Antipolis (P.S., C.D.F., J.-P.V., J.M.), 06560 Valbonne, France; and Institut für Zellbiochemie und Klinische Neurobiologie, Universität Hamburg (H.-J.K.), D-20246 Hamburg, Germany

Address all correspondence and requests for reprints to: Alain Beaudet, M.D., Ph.D., Montreal Neurological Institute, McGill University, 3801 University Street, Montréal, Québec, Canada H3A 2B4. E-mail: mcin{at}musica.mcgill.ca


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Internalization of G protein-coupled receptors is crucial for resensitization of phosphorylation-desensitized receptors, but also for their long term desensitization through sequestration. To elucidate the mechanisms regulating cell surface availability of the somatostatin (SRIF) receptor subtype sst5, we characterized its internalization properties in transfected COS-7 cells using biochemical, confocal microscopic, and electron microscopic techniques. Our results demonstrated rapid and efficient sequestration of specifically bound [125I]Tyr0-D-Trp8-SRIF (up to 45% of bound radioactivity). Combined immunocytochemical detection of sst5 and visualization of a fluorescent SRIF analog by confocal microscopy revealed that whereas the internalized ligand progressively clustered toward the cell center with time, immunoreactive receptors remained predominantly associated with the plasma membrane. The preservation of cell surface receptors was confirmed by binding experiments on whole cells revealing a lack of saturability of [125I]Tyr0-D-Trp8-SRIF binding at 37 C. Binding was rendered saturable by the drug monensin, showing that receptor recycling played a key role in the preservation of cell surface receptors. Electron microscopy demonstrated that in addition to receptor recycling, internalization of receptor-ligand complexes triggered a massive recruitment of sst5 receptor molecules from intracellular stores to the membrane. This combination of recycling and recruitment of spare receptors may protect sst5 from long term down-regulation through sequestration and, therefore, facilitate extended SRIF signaling.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
SOMATOSTATIN [somatotropin release-inhibiting factor (SRIF)] is widely distributed throughout the mammalian central nervous system and periphery (for review, see Refs. 1, 2). It exists in one of two forms, derived from a single gene: SRIF-14 and its N-terminally extended form, SRIF-28. Both forms are involved in the regulation of hormone release from the anterior pituitary (3) and from peripheral glands (4, 5). They also act as neurotransmitters and neuromodulators in the central and peripheral nervous systems (1) and as regulators of cell proliferation in peripheral tissues, including SRIF receptor-expressing tumors (6, 7, 8, 9).

The actions of SRIF are mediated through a family of G protein-coupled membrane receptors. The known receptors are encoded by five individual genes, designated sst1-sst5 (10, 11, 12, 13, 14, 15). One of the cloned receptor genes, sst2, gives rise to two splice variants, termed sst2A and sst2B, whereas the other receptor genes lack introns. Although these different receptor subtypes have been linked to a variety of signal transduction pathways (for review, see Ref. 16), their individual roles have yet to be fully elucidated. In the pituitary, sst2 and sst5 appear to play a major role in mediating SRIF’s regulatory influence on the release of pituitary hormones such as GH (17). In the pancreas, sst5 is reportedly a key player in the regulation of insulin release by SRIF (5). All five sst receptor subtypes are present in mammalian brain (18, 19, 20). Whereas sst1–3 appear to be abundantly expressed in brain, the distribution of sst4 and sst5 is much more limited (18, 19, 20, 21, 22, 23, 24, 25, 26).

All five SRIF receptors, with the possible exception of sst4, have been shown to internalize upon ligand activation (27, 28, 29, 30, 31). Internalization of receptor-ligand complexes has been shown to play a predominant role both for resensitization through dephosphorylation (32) and for desensitization through sequestration (33, 34) of G protein-coupled receptors. Furthermore, recent studies on a variety of G protein-coupled receptors, including those of the sst family (35), have suggested that internalization might subserve specific signaling functions either through endosomal signaling (36) or through activation of mitogen-activated protein kinase pathways independent of G protein recruitment (37, 38).

A striking feature of sst receptor internalization is the wide spectrum of maximal capacities and intracellular trafficking patterns reported between the various subtypes (27, 28, 29, 30). For example, in COS-7 cells transfected with the sst1 receptor, SRIF only poorly internalizes and remains clustered beneath the plasma membrane at all times (28). By contrast, in COS-7 cells transfected with sst2A, internalization of fluorescent SRIF is extremely efficient and characterized by a rapid down-regulation of cell surface receptors and the formation of small intracytoplasmic particles reminiscent of endosomes (28). Internalization of immunoreactive sst3 receptors, as studied in transfected HEK-293 (30) and RIN 1046–38 cells (29), is also highly efficient and gives rise to the same type of intracellular labeling pattern as that observed in cells transfected with sst2A. In the case of sst4, major species differences have been reported between rat and human clones. Whereas the native rat sst4 receptor does not internalize following SRIF binding (29, 30), the human sst4 internalizes well (27). Species differences were also observed in the case of sst5; rat sst5 internalizes only in response to stimulation with SRIF-28 and not SRIF-14 (29, 30), whereas human sst5 does internalize when stimulated with D-Trp8-SRIF (39).

The aim of the present study was to further characterize the properties and pattern of SRIF-induced internalization of the sst5 receptor subtype, in an attempt to gain further insight into the regulation of this receptor. We employed biochemical, confocal, and electron microscopic techniques to track sst5 and SRIF through the events following SRIF-induced internalization. We show that a constant population of functional sst5 receptors is maintained at the cell surface at all times through a process of receptor recycling and recruitment of intracellular sst5 proteins. We propose that this mechanism may protect sst5 from long term desensitization.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Cell culture and transfection
The monkey kidney epithelium-derived cell line COS-7 was cultured in DMEM (Life Technologies, Inc., Burlington, Canada) supplemented with 10% FBS (Harlan Bioproducts, Inc., Indianapolis, IN) and 1% penicillin/streptomycin (Life Technologies, Inc.). The cells were transfected with 1 µg/ml of either pcD2 or pcDNA3 eukaryotic expression vectors containing the rat sst5 receptor complementary DNA (cDNA; provided by Dr. A. M. O’Carroll, NIMH) according to the DEAE-dextran/chloroquine procedure. After 48–72 h, cells were harvested and plated onto poly-L-lysine-coated coverslips in four-well tissue culture plates for light microscopy or directly into the wells for electron microscopy. Cells for radioactive ligand binding assays were grown in 12-mm culture dishes.

Preparation of cell homogenates
Confluent COS-7 cells were washed and scraped into ice-cold Tris-buffered saline (pH 7.5). Subsequently, the cells were centrifuged for 5 min in microfuge tubes at 13,000 x g and resuspended in hypotonic TE buffer (5 mM EDTA and 10 mM Tris-HCl, pH 7.5). Membrane homogenates were then sonicated, recentrifuged at 13,000 x g for 30 min at 4 C, and resuspended in the same buffer.

Binding of 125I-Tyr0-D-Trp8-SRIF to COS-7 cells
To assess the pharmacological properties of sst5 receptors in transfected COS-7 cells, binding experiments were performed on freshly prepared membranes. Briefly, 25 µg membranes were incubated with concentrations of [125I]Tyr0-D-Trp8-SRIF (2000 Ci/mmol; hereafter referred to as [125I]SRIF) ranging from 0.1–100 nM for 30 min at 25 C in 250 µl Tris-HCl (pH 7.5) containing 2 mM MgCl2, 0.1% BSA (Roche Molecular Biochemicals, Laval, Canada), and 0.8 mM 1,10-phenanthroline (Sigma, St. Louis, MO) to prevent peptide degradation. Binding was terminated by the addition of 2 ml ice-cold buffer followed by filtration through glass-microfiber filters (GF/C, Whatman, Clifton, NJ) preincubated in 0.5% polyethylenimine. After washing twice with 2 ml ice-cold buffer, the radioactivity retained on the filters was counted in a {gamma}-counter. Nonspecific binding was measured in the presence of 1 µM nonlabeled D-Trp8-SRIF (Sigma). The dissociation constant (Kd) and maximal binding capacity (Bmax) were derived from Scatchard analysis of the data.

For confocal microscopic tracking of internalized ligand, the pH-insensitive dye Bodipy 576/589 (40) (Molecular Probes, Inc., Eugene, OR) emitting red fluorescence was covalently conjugated to the degradation-resistant SRIF analog D-Trp8-SRIF in the {alpha} position (for more detail on preparation and purification, see Ref. 28). To compare the affinity of this fluorescent SRIF analog (hereafter referred to as fluo-SRIF) toward sst5 with those of native molecular forms of SRIF and other synthetic SRIF analogs, 25 µg membranes were incubated with 0.3 nM [125I]SRIF in the presence of increasing concentrations of SRIF-14, SRIF-28, D-Trp8-SRIF, Tyr0-D-Trp8-SRIF (all from Sigma), or fluo-SRIF ranging from 1 pM to 1 µM. Binding was performed for 30 min at room temperature in 250 µl Tris-HCl buffer, pH 7.5, containing 2 mM MgCl2, 0.1% BSA, and 0.8 mM 1,10-phenanthroline. The experiment was terminated, and radioactivity was counted as described above.

To characterize the kinetics of sst5 internalization in transfected COS-7 cells, internalization assays were carried out on whole cells in 12-mm dishes containing 2 x 105 cells. After discarding the culture medium, cells were equilibrated for 10 min at 37 C in Earle’s buffer (140 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 0.9 mM MgCl2·6H20, and 25 mM HEPES) containing 0.8 mM phenanthroline, 0.1% D-glucose, and 1% BSA in the presence or absence of 10 µM phenylarsine oxide (PAO; Sigma), a drug that blocks endocytosis (but also many other cellular functions) through chemical reaction with sulfhydryl groups (41), or of 25 µM monensin (Sigma), which inhibits the membrane recycling process by raising the pH within endosomes and thereby preventing the dissociation of receptor and ligand (41). Some experiments were carried out in the presence of 70 µM cycloheximide (Sigma) (41), a protein synthesis inhibitor, in which case the preincubation period was increased to 2 h. Equilibration buffer was then replaced with 250 µl binding buffer containing 0.3 nM [125I]SRIF for 3–40 min (time course) or 0.1–100 nM [125I]SRIF for 45 min (saturation), both at 37 C. In time-course experiments, cells were then washed twice with pure equilibration buffer or a hypertonic acid buffer (Earle’s buffer containing 0.2 M acetic acid and 0.5 M NaCl, pH 4) to strip off surface-bound radioactivity (41). In saturation experiments, the cells were washed with equilibration buffer. All cells were harvested with 1 ml 0.1 M NaOH, and associated radioactivity was counted in a {gamma}-counter. Nonspecific binding was measured in the presence of an excess (1 µM) of nonlabeled D-Trp8-SRIF.

Internalization of {alpha}-Bodipy Red-D-Trp8-SRIF in sst5-transfected COS-7 cells
COS-7 cells transfected with cDNA encoding sst5 were preincubated for 10 min at 37 C in Earle’s buffer containing 0.8 mM phenanthroline, 0.9 g/ml D-glucose, and 0.2% BSA and then incubated for 5–60 min in the presence of 10 nM fluo-SRIF in the same buffer. To determine nonspecific binding, 1 µM nonfluorescent D-Trp8-SRIF was added to the incubation medium. To evaluate temperature dependence, additional cells were incubated at 4 C. At the end of the incubation, cells were rinsed twice for 2 min each time with cold Earle’s buffer and air-dried. To selectively observe internalized fluo-SRIF, cells were washed twice with hypertonic acid buffer, pH 4, before rinsing and air-drying. To determine whether fluo-SRIF internalization was clathrin-mediated, cells were preincubated for 30 min in equilibration buffer containing either 20 µM PAO or 0.45 sucrose (two compounds known to inhibit clathrin-mediated endocytosis) (41). They were then incubated with fluo-SRIF in the presence of PAO or sucrose, respectively, and treated as described above. Air-dried cells were examined under a Carl Zeiss laser scanning microscope attached to an Axiovert 100 inverted microscope (Carl Zeiss Canada Ltd., Con Mills, Canada). Images were acquired as single optical sections through the center of the cells at 16 scans/frame in the LUTS mode. After the initial adjustment of laser power and contrast, all images of cells from 1 experiment were acquired using identical settings of the confocal unit. The images were processed using Photoshop version 4.0.1 and Illustrator version 7.0 (both from Adobe Systems, Inc., San Jose, CA) on an IBM-compatible computer.

Pulse-chase experiments: confocal microscopy
To examine the fate of SRIF in parallel with that of sst5 receptors in the course of ligand-induced internalization, transfected COS-7 cells were preincubated for 90 min at 37 C in DMEM containing 70 µM cycloheximide, a protein synthesis inhibitor, followed by 5- to 10-min equilibration at 4 C in Earle’s buffer containing 70 µM cycloheximide, 0.8 mM phenanthroline, 0.9 g/ml D-glucose, and 0.2% BSA. Cycloheximide was also included in the incubation medium in all following steps before the final rinses. After exposure to 10 nM fluo-SRIF for 30 min at 4 C in supplemented Earle’s buffer, the incubation medium containing the peptide was aspirated and replaced with supplemented Earle’s buffer at 37 C without the ligand, and internalization was allowed to proceed for 0, 5, 10, 20, 40, or 60 min, respectively. Finally, the cells were subjected to hypertonic acid wash followed by air-drying. Additional cells from the same transfection were incubated with 10 nM nonlabeled D-Trp8-SRIF in lieu of fluo-SRIF. These cells were incubated for 30 min at 4 C, chased at 37 C as described above, rinsed twice in 0.1 M phosphate buffer, pH 7.4 (PB), and fixed with 4% paraformaldehyde (PFA) in the same buffer at room temperature. Subsequently, the cells were rinsed twice in PB and twice in 0.1 M Tris-buffered saline, pH 7.4 (TBS). They were then incubated overnight at 4 C with 0.2 µg/ml affinity-purified rabbit anti-sst5 antibody (for details on antibody generation and characterization, see Refs. 26, 30) in TBS containing 0.5% normal goat serum (NGS) and 0.05% Triton X-100. The next day, the cells were rinsed twice in TBS and incubated for 40 min at room temperature with goat antirabbit-Cy3 secondary antibodies (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) diluted 1:800 in TBS followed by two final rinses in TBS and mounting in Aquamount (Polyscience, Markham, Canada). As controls, transfected cells were immunostained under the same conditions, but without stimulation by D-Trp8-SRIF. All specimens were examined under a confocal microscope as described above.

Pulse-chase experiments: electron microscopy
To follow the fate of internalized sst5 receptors at the subcellular level, a series of pulse-chase experiments was carried out as described above. However, for the sake of better ultrastructural preservation, cycloheximide was excluded from all incubation buffers, and pulse-labeling with 20 nM D-Trp8-SRIF was performed at 10 C, followed by chase periods of 0, 10, and 40 min at 37 C. Subsequent to this pulse-chase protocol, cells were fixed for 20 min in 2% acrolein/2% PFA in 0.1 M PB followed by another 20 min in 2% PFA alone. They were then briefly washed in 0.1 M TBS, exposed for 30 min to a preincubation solution consisting of 3% NGS in 0.1 M TBS, and incubated overnight at 4 C with 0.4 µg/ml sst5 receptor antibody along with 0.02% Triton X-100 and 0.5% NGS in 0.1 M TBS. After primary antibody incubation, the cells were repeatedly rinsed in 0.01 M PBS, and nonspecific sites were blocked with a mixture of 0.1% gelatin and 0.8% BSA in 0.01 M PBS. Cells were then incubated with a 1:50 dilution of goat antirabbit IgG-gold (AuroProbe One GAR, Amersham Pharmacia Biotech, Arlington Heights, IL) at room temperature for 2 h, fixed with 2% glutaraldehyde in 0.01 M PBS, and rinsed in 0.2 M citrate buffer, after which the reaction was enhanced by incubation with ionic silver (IntenSE M Silver Enhancement Kit, Amersham Pharmacia Biotech). After a rinse in 0.1 M PB, cells were postfixed in a solution of 2% osmium tetroxide in 0.1 M PB in the dark for 10 min, dehydrated in graded concentrations of ethanol, and embedded in Epon. Ultrathin sections were cut and impregnated with uranyl acetate and lead citrate according to standard electron microscopy protocols before examination with a JEOL 100CX transmission electron microscope (JEOL USA, Inc., Peabody, MA).

For quantification, an average of 20 separate cell profiles were obtained from each experimental condition in every individual experiment. The distribution of immunogold particles was then analyzed using computer-assisted morphometry (Biocom, Les Ulis, France). Specifically, the total numbers of gold particles associated with the plasmalemma and located within the intracellular compartment were counted separately and normalized as a function of membrane length and area of cell sampled, respectively. The distance between each intracellular receptor and the plasmalemma was also measured and distributed into bins at increasing distance from the cell surface. Finally, a frequency distribution of intracellular particles and the ratio between intracellular and membrane-associated receptors were calculated for each experimental condition. Statistical significance was verified using Student’s t test, (two-tailed) for distant measurements and Mann-Whitney or Wilcoxon tests (two tailed) for membrane/cell interior ratios. All calculations and statistical analyses were performed using Excel 5.0 (Microsoft Corp., San Francisco, CA).


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Binding of [125I]SRIF to transfected COS-7 cell membranes
[125I]SRIF binding to membranes prepared from COS-7 cells transfected with cDNA encoding the rat sst5 receptor was specific and saturable. Saturation experiments yielded a linear Scatchard plot, demonstrating the presence of a single binding site with a Kd of 0.3 ± 0.1 nM (Fig. 1aGo). The maximal binding capacity was 92 ± 5 fmol/mg (n = 3; Fig. 1aGo). Membranes prepared from nontransfected cells were totally devoid of [125I]SRIF binding (not shown).



View larger version (21K):
[in this window]
[in a new window]
 
Figure 1. Kinetics of [125I]Tyr0-D-Trp8-SRIF binding to membranes of COS-7 cells transfected with cDNA encoding the sst5 receptor. Membranes (25 µg) were incubated with increasing concentrations of (a) or with 0.3 nM (b) [125I]Tyr0-D-Trp8-SRIF for 30 min at 25 C. Specific binding was calculated as total binding minus binding in the presence of 1 µM D-Trp8-SRIF. a, Scatchard representation of saturation data. b, Competitive binding inhibition using {alpha}-Bodipy-D-Trp8-SRIF ({circ}), D-Trp8-SRIF (•), Tyr0-D-Trp8-SRIF ({triangleup}), SRIF-28 ({blacksquare}), and SRIF-14 ({square}) as competitors. For IC50 values, see Table 1Go.

 
When tested for their ability to compete against [125I]SRIF for binding to sst5, the native molecular forms and various synthetic analogs of SRIF exhibited markedly different potencies (Fig. 1bGo and Table 1Go). SRIF-28 showed the highest affinity (IC50 = 0.42 nM) and was 5 times more potent than SRIF-14 in displacing specific binding from transfected sst5 receptors (IC50 = 2.1 nM; Fig. 1bGo and Table 1Go). The two synthetic analogs D-Trp8-SRIF and Tyr0-D-Trp8-SRIF displayed identical affinities for sst5 and were almost as potent as SRIF-28 in competing for binding at this receptor (IC50 = 0.6 nM; Fig. 1bGo and Table 1Go). The fluorescent analog {alpha}-Bodipy-D-Trp8-SRIF also competed with specific [125I]SRIF binding, but with a potency similar to that of SRIF-14 (IC50 = 2.3 nM; Fig. 1bGo and Table 1Go).


View this table:
[in this window]
[in a new window]
 
Table 1. IC50 values for the various compounds

 
Association of [125I]SRIF to whole transfected COS-7 cells
In time-course experiments, association of [125I]SRIF at 37 C to whole COS-7 cells expressing sst5 reached equilibrium approximately 20 min after the onset of the experiment (Fig. 2aGo). At that time, 45% of the radioactivity associated with the cells was acid wash resistant, i.e. was no longer surface bound (Fig. 2aGo). After preincubation and labeling of the cells in the presence of the endocytosis inhibitor PAO, the amount of radioactivity specifically associated with the cells at equilibrium was about 55% of that measured in the absence of treatment (Fig. 2aGo). This proportion was therefore the same as the acid-washable (i.e. cell surface) fraction in experiments carried out in the absence of PAO. Accordingly, the radioactivity associated with cells incubated in the presence of PAO was almost entirely washed away by hypertonic acid buffer treatment, indicating that PAO totally prevented internalization (Fig. 2aGo).



View larger version (18K):
[in this window]
[in a new window]
 
Figure 2. Kinetics of [125I]Tyr0-D-Trp8-SRIF binding to whole COS-7 cells expressing the rat sst5 receptor. Cells were incubated with 0.3 nM [125I]SRIF for 3–40 min (a) or with increasing concentrations of [125I]SRIF for 45 min (b) at 37 C. a, Time course. Experiments were performed in the presence (circles) or absence (squares) of 10 µM PAO, followed (closed symbols) or not (open symbols) by a hypertonic acid wash to strip off cell surface binding. b, Saturation. Experiments were performed in the absence of any drug (•) or in the presence of 10 µM PAO ({circ}), 25 µM monensin ({triangleup}), 70 µM cycloheximide ({blacksquare}), or monensin and cycloheximide ({square}).

 
In saturation experiments, association [125I]SRIF to whole COS-7 cells was not saturable even with 1 µM of the ligand (Fig. 2bGo). Incubation in the presence of the protein synthesis inhibitor, cycloheximide, yielded the same result (Fig. 2bGo). By contrast, the amount of [125I]SRIF associated with cells in the presence of PAO, i.e. bound to receptors immobilized at the cell surface, was saturable, indicating that the lack of saturation observed in baseline conditions was linked to receptor dynamics (Fig. 2bGo). In the presence of the receptor recycling inhibitor monensin or of monensin together with cycloheximide, saturation with [125I]SRIF was also observed (Fig. 2bGo). The maximal binding capacity under these conditions was about twice as high as that obtained in the presence of PAO (Fig. 2bGo), indicating that part, but not all, of the baseline binding could be accounted for by receptor recycling.

Internalization of fluo-SRIF in sst5-transfected COS-7 cells
Incubation of transfected COS-7 cells with 10 nM fluo-SRIF for 40 min at 4 C (data not shown) or 37 C (Figs. 3aGo and 4Go) resulted in intense fluorescent labeling of approximately 20% of the cells. This labeling was specific, in that it was no longer apparent in the presence of a 100-fold excess (1 µM) of nonradioactive D-Trp8-SRIF (Fig. 3bGo). When the incubation was carried out at 4 C, or at 37 C in the presence of 20 µM PAO or 0.45 M sucrose, the labeling remained confined to the periphery of the cells (Fig. 3cGo). This peripheral labeling was completely abolished by acid wash, confirming that it was exclusively surface bound (Fig. 3dGo).



View larger version (81K):
[in this window]
[in a new window]
 
Figure 3. Binding of fluo-SRIF to COS-7 cells transfected with cDNA encoding the sst5 receptor. a, Incubation of transfected cells for 40 min at 37 C in the presence of 10 nM fluo-SRIF results in intense intracytoplasmic labeling of approximately 10–20% of the cells. b, This binding is specific, in that it is abolished in the presence of 1 µM of the nonlabeled agonist, D-Trp8-SRIF. c, When the incubation was carried out in the presence of 20 µM PAO, the labeling remained pericellular as opposed to intracellular. d, This pericellular labeling was completely abolished by the hypertonic acid wash, indicating that it is confined to the cell surface. Single optical sections were taken through the center of the cells. Scale bar, 10 µm.

 


View larger version (69K):
[in this window]
[in a new window]
 
Figure 4. Internalization of fluo-SRIF in sst5-transfected COS-7 cells. Incubation of transfected cells with 10 nM fluo-SRIF for 5–40 min at 37 C gives rise to intense, punctate fluorescent labeling, which increases over time (left column). Hypertonic acid wash reveals that the bulk of this labeling is intracellular (right column). After 5- to 10-min incubation, intracellular labeling was mainly found at the periphery of the cells. After 20 min, intensely fluorescent particles filled most of the cytoplasm, sparing the nucleus. At 40 min, fluo-SRIF had accumulated in the perinuclear zone. Single optical sections were taken through the nuclear plane. Scale bar, 10 µm.

 
By contrast, after incubation at 37 C in the absence of PAO, bound fluo-SRIF was evident throughout the cytoplasm of the cells (Figs. 3aGo and 4Go). Increasing the incubation time from 5 to 60 min resulted in a continuous increase in fluorescent labeling (Fig. 4Go, left column). Hypertonic acid wash revealed that this increase in fluorescent labeling was mainly due to an accumulation of fluorescent peptide inside the cells (Fig. 4Go, right column). At all time intervals, acid-resistant binding took on the form of small fluorescent particles reminiscent of endosomal organelles (Fig. 4Go). After 5 min of internalization, these organelles remained relatively peripheral. After 10 min, they were visible deeper in the cytoplasm, and after 20 min, fluo-SRIF filled out most of the cytoplasm, sparing the nucleus. Finally, after 40 (Fig. 4Go) and 60 (not shown) min, the fluorescent ligand was concentrated in the center of the cell proximal to the nucleus.

Parallel tracking of fluo-SRIF and sst5 receptor immunoreactivity in the course of ligand-induced internalization
In pulse-chase experiments (n = 3), in which the cells were preincubated at 4 C with or without 10 nM nonlabeled D-Trp8-SRIF or with 10 nM fluo-SRIF followed by sst5 immunolabeling or air-drying, respectively, the fate of the receptor and the ligand in the course of the internalization process were followed in parallel. These experiments were carried out after 90 min of preincubation with 70 µM cycloheximide and in the presence of cycloheximide throughout to suppress receptor neosynthesis during the course of the experiment. Cells incubated with fluo-SRIF were acid-washed after the labeling period for selective visualization of internalized ligand.

At time zero, i.e. at the end of the 4 C pulse, no intracellular ligand fluorescence was evident (Fig. 5Go, right column). Immunocytochemistry revealed that at this time point, receptors were present both at the cell surface and in a prominent intracellular pool (Fig. 5Go, left and middle columns). In cells that were not exposed to D-Trp8-SRIF, this pattern of receptor distribution showed little change over time (Fig. 5Go, left column). By contrast, dramatic movements of both receptor and ligand were observed in cells incubated with SRIF (Fig. 5Go, middle and right columns). At short time intervals (5 and 10 min), internalized fluo-SRIF was confined to the periphery of the cells. At the same time points, sst5 immunoreactivity was still visible at the cell surface and within the intracellular core. After 20 min of chase at 37 C, internalized fluo-SRIF was visible throughout the cytoplasm, in the form of small fluorescent vesicles. At the same time point, sst5 immunofluorescence was still evident at the cell surface. However, the brightness of the central cytoplasmic pool of receptor immunofluorescence was greatly reduced, and the whole cytoplasm was pervaded by punctate receptor immunoreactivity. The most dramatic differences between ligand and receptor labeling patterns were observed after long periods of chase (40 and 60 min). At those time points, internalized fluo-SRIF became progressively more concentrated in the cell center, near the nucleus. By contrast, receptor immunoreactivity was entirely confined to the cell periphery.



View larger version (61K):
[in this window]
[in a new window]
 
Figure 5. Parallel tracking of fluo-SRIF and sst5 in the course of internalization. In COS-7 cells fixed immediately after pulse labeling with D-Trp8-SRIF at 4 C, no internalization of the ligand is observed (0', right column). At this time point, immunoreactive receptors are present both at the cell surface and in a prominent cytoplasmic pool (0', left and middle columns). In nonstimulated cells, this pattern of receptor distribution changes only minimally over time (left column). By contrast, in stimulated cells, immunoreactive receptors are first (5–20 min) apparent on the plasma membrane and within the cytoplasm and later (40–60 min) exclusively associated with the plasma membrane (middle column). During the same time, internalized fluo-SRIF (right column) is first confined to the cell periphery (5 and 10 min) and is then progressively mobilized toward the center of the cell (20–60 min). All cells exposed to fluo-SRIF were subjected to hypertonic acid wash to strip off surface-bound ligand before air-drying and imaging. All images were taken in the transnuclear plane and acquired using identical settings of the confocal unit. Scale bar, 10 µm.

 
Electron microscopic tracking of internalized sst5 receptors
Transfected COS-7 cells stimulated for 30 min at 10 C with 20 nM D-Trp8-SRIF were analyzed by silver-enhanced immunogold sst5 immunocytochemistry after chase periods of 0, 10, and 40 min at 37 C and compared with cells incubated in parallel but not exposed to the agonist. At all time points and under both stimulated and nonstimulated conditions, sst5 immunoreactivity was detected both intracytoplasmically and on the plasmalemma of the cells (Fig. 6Go). Quantitatively, however, pronounced changes in the distribution of gold particles were observed between membrane and cytoplasm in cells exposed to the agonist. At 0 min, the ratio between plasma membrane-associated receptors and intracellular gold particles was small both in nonstimulated cells and in cells exposed to D-Trp8-SRIF, indicating that the bulk of immunoreactive receptors was located intracellularly (Fig. 7Go). At 10 min, the ratio between surface receptors and intracellular immunoreactivity remained almost unchanged in cells unexposed to the agonist (Fig. 7Go). By contrast, in stimulated cells there was a marked increase in this ratio, reflecting a net movement of receptors from the cytoplasm to the membrane compared with that at 0 min (Fig. 7Go; P <= 0.01, by Mann-Whitney U test, two-tailed) and with nonstimulated cells at 10 min (Fig. 8Go; P <= 0.01, by Wilcoxon two-sample test, two-tailed). After 40 min of chase at 37 C, the ratio between cell surface-associated and intracellular receptors still remained stable in nonstimulated cells and returned to baseline in cells exposed to the agonist (Fig. 7Go).



View larger version (174K):
[in this window]
[in a new window]
 
Figure 6. Electron microscopic detection of sst5 immunoreactive receptors without (a) and with (b) exposure to D-Trp8-SRIF. Transfected COS-7 cells were incubated for 30 min at 10 C with Earle’s buffer containing (b) or not (a) 20 nM D-Trp8-SRIF followed by 10 min of chase at 37 C, allowing for internalization to occur. Subsequently, the cells were immunolabeled using the silver-enhanced immunogold technique. In both stimulated and nonstimulated cells, immunolabeling is detected on the plasma membrane as well as in the subplasmalemmal cytoplasm. In cells exposed to buffer alone, intracytoplasmic gold particles are relatively scarce and predominantly associated with vesicular elements (arrows). By contrast, in cells exposed to D-Trp8-SRIF, immunoreactive sst5 receptors are much more abundant than in controls both in association with the plasma membrane and in the subplasmalemmal zone of the cytoplasm (arrows). Scale bar, 450 nm.

 


View larger version (18K):
[in this window]
[in a new window]
 
Figure 7. Effects of SRIF exposure on membrane-associated/intracellular sst5 receptor ratios. Cells were pulse labeled (black bars) or not (white bars) with 20 µM D-Trp8-SRIF at 10 C, followed by chase periods of 0 (baseline), 10, and 40 min at 37 C. Receptors were visualized by electron microscopic immunocytochemistry using immunogold. Ratios between membrane-associated and intracellular receptors were calculated for each time point and each experimental condition after normalizing the number of gold particles associated with the plasmalemma for membrane length and the number of intracellular gold particles for area of cell sampled. Data are expressed as the mean ± SEM of 20 different cells/condition.

 


View larger version (142K):
[in this window]
[in a new window]
 
Figure 8. Electron microscopic distribution of immunoreactive sst5 receptors after 30 min pulse-labeling with D-Trp8-SRIF at 10 C and 10-min (a–c) or 40-min (d) chase at 37 C. a, After 10 min of chase, prominent sst5 immunolabeling is still evident at the level of the plasma membrane. Note the association of intracellular receptors with tubular endosome-like compartments (arrows). b, Also after 10 min of chase, a single large endosome (arrows) containing at least 10 gold particles is observed deeper in the cytoplasm. (c) At the same time point, a gold particle is observed in association with an invaginating coated pit (arrows). d, After 40 min of chase, a clathrin-coated vesicle containing a gold particle is located next to the plasma membrane, whereas other immunoreactive receptors are associated with an endosome (arrows). Scale bars: a, 400 nm; c, 200 nm; b and d, 185 nm.

 
In the cell interior, most of the gold particles were associated with vesicular organelles under both stimulated and nonstimulated conditions (Fig. 6Go, arrows). Only occasionally were stray particles found free floating in the cytoplasm. A few immunolabeled receptors were observed in close apposition to the nuclear envelope, but never inside the nucleus proper. No gold particles were detected in lysosomes. There were, however, marked differences in terms of intracellular receptor distribution depending on whether the cells were stimulated with SRIF. In cells exposed to SRIF, gold particles were detected more frequently in clathrin-coated pits at the cell membrane as well as in coated vesicles and endosomal organelles in the subplasmalemmal zone than in nonexposed cells (Fig. 8Go). In fact, quantitative data showed that whereas under baseline conditions the relative frequency of intracellular gold particles in bins of increasing distance from the plasma membrane was very similar in stimulated and nonstimulated cells, after 10 min of chase at 37 C, the mean distance of immunoreactive receptors from the membrane was significantly decreased (from 2–3 to 0.25–1 µM; P < 0.01 compared with 0 min) in cells exposed to the ligand, but not in those that were not stimulated by SRIF, indicating a SRIF-induced mobilization of receptors from the cell center to the periphery (Fig. 9Go). After 40 min of chase, the frequency distribution of gold particles remained virtually unchanged in cells that were not exposed to D-Trp8-SRIF, whereas in stimulated cells, two peaks of receptor density were apparent, one at 0.25–0.5 µm from the membrane and another at 2–3 µM (significantly different from 0 min, P <= 0.01; not significantly different from 10 min, P = 0.06; Fig. 9Go).



View larger version (25K):
[in this window]
[in a new window]
 
Figure 9. Intracellular mobilization of sst5 receptors in transfected COS-7 cells after ligand exposure. Electron microscopic distribution of intracellular immunoreactive sst5 receptors in cells pulse-labeled or not with D-Trp8-SRIF. Data from one representative experiment corresponding to the number of gold particles counted within bins of distance from the membrane surface. The inset line graphs are a different representation of the same set of data to underscore the dynamics of intracellular receptor trafficking. Immediately after pulse labeling, the maximum intracellular receptor density is found 2–3 µm from the membrane in both stimulated and nonstimulated cells (0 min). In nonstimulated cells, this pattern of distribution remains virtually unchanged throughout the experiment. By contrast, after 10 min of chase at 37 C, D-Trp8-SRIF-stimulated cells show a significant mobilization of intracellular receptors to the subplasmalemmal zone. After 40 min, two peaks of receptor density are apparent, one deep inside the cytoplasm and one at 0.25 µm from the membrane, indicative of a prolonged up-regulation of receptor numbers in the subplasmalemmal zone.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The present study tracks the SRIF receptor subtype sst5 and its ligand through internalization and the intracellular trafficking events in its wake. It shows that even though sst5-SRIF complexes are internalized via the endocytic pathway, the receptor is regulated in such a way that a high density of cell surface binding sites is maintained throughout the period investigated. Combined biochemical and electron microscopic data indicate that both recycling of internalized receptor molecules and recruitment of spare receptors from an intracytoplasmic pool contribute to this phenomenon.

The pharmacological characteristics of recombinant rat sst5 in our experiments conformed to those obtained by others in various transfection systems (42; for review, see Ref. 43). Thus, as in previous studies investigating both rat and human sst5 in transfected CHO-K1 or COS-7 cells (13, 42, 43), SRIF-28 was approximately 5 times as potent as SRIF-14 in displacing radioiodinated Tyr0-D-Trp8-SRIF from the sst5 binding site. The synthetic analogs D-Trp8-SRIF and Tyr0-D-Trp8-SRIF showed identical affinities for the receptor and were almost as potent as SRIF-28 (IC50 = 0.6 nM). In CHO-K1 cells, D-Trp8-SRIF exhibited an even higher potency in displacing [125I]CGP23996 from the sst5-binding site and was more potent in doing so than SRIF-28 itself (IC50 = 0.002 nM) (42). Finally, the fluorescent ligand employed in our study, {alpha}-Bodipy Red-D-Trp8-SRIF, was virtually equipotent with SRIF-14 in competing for [125I]D-Trp8-SRIF binding at the sst5 site, validating its usefulness as a high affinity marker of sst5 receptors.

Previous studies have demonstrated that both human (27, 39) and rat (29, 30) sst5 are internalized in the presence of SRIF in a variety of cell lines. In HEK cells transfected with cDNA encoding rat sst5 (30) as well as in RIN 1046–38 insulinoma cells transfected with tagged rat sst5 (29), this process was ligand specific, in that internalization was observed after exposure to SRIF-28, but not to SRIF-14. The present results indicate that in COS-7 cells expressing the rat sst5 receptor, as in CHO-K1 cells expressing the human sst5 receptor (39), D-Trp8-SRIF-14 is able to efficiently induce sst5 internalization. Whether this property is dependent upon the cell lines used or reflects specific properties of this SRIF analog, which could be linked to its near equipotency with SRIF-28 at the sst5 binding site, remains to be determined.

The internalization process observed in sst5-transfected COS-7 cells is rapid, reaching a plateau within 20 min (t1/2 = 10 min). These kinetics are comparable to those of SRIF internalization via the rat sst2A receptor in the same cell type (28). With 45% of total specifically bound radioactivity, however, internalization via sst5 does not reach the same capacity as sst2A-mediated endocytosis (85%; 28). In CHO-K1 cells transfected with individual human sst subtypes, on the other hand, sst5 internalized more efficiently than sst2A (66%; 27).

As in the case of sst2A (28), fluo-SRIF internalization via sst5 was entirely blocked by incubation with the endocytosis inhibitor PAO or in hypertonic sucrose, indicating that it is dependent on the formation of clathrin-coated pits (41). Immunoelectron microscopic experiments confirmed that this was indeed the case, by demonstrating SRIF-induced mobilization of sst5 in clathrin-coated pits and vesicles. Molecular studies previously demonstrated the presence of both positive and negative sequence motifs for internalization in the intracellular C-terminal domain of the cloned human and rat sst5 receptors (30, 39), indicating a pivotal role for the C-terminus in mediating internalization. Moreover, a variant of the consensus sequence NPXXY for binding of G protein-coupled receptors to the clathrin-adaptor molecule ß-arrestin (for review, see Refs. 34, 41) is present in position 300–304 (in fact, NPLLY) at the C-terminal end of the cloned rat receptor (13) in exactly the same position as in the human sst5 molecule (39). Although direct evidence is still missing, these data suggest that sst5 might, like other G protein-coupled receptors, interact with clathrin through binding to ß-arrestin.

Combined confocal microscopic tracking of fluo-SRIF and sst5 receptors in cells pretreated with the protein synthesis inhibitor cycloheximide allowed us to determine the fate of receptor-ligand complexes after ligand-induced internalization. Five to 10 min after transfer of fluo-SRIF-labeled COS-7 cells from 4 to 37 C, internalized ligand was confined to the periphery of the cells in the form of small fluorescent particles. By 20 min after the onset of internalization, these endosome-like particles pervaded most of the cytoplasm. Finally, after longer time intervals (40 and 60 min), the ligand had accumulated inside the cytoplasm and concentrated in the center of the cells in close proximity to the nucleus. This course of events is similar to that observed in the same type of cells transfected with cDNA encoding the rat sst2A receptor (28). By contrast, cells transfected with the sst1 receptor barely sequester fluo-SRIF (28). A pattern of endocytic events similar to that seen here was also observed in COS-7 cells transfected with the NT1 neurotensin receptor (44), in CHO cells transfected with the cholecystokinin receptor (45), and in Kirsten murine sarcoma virus-transformed rat kidney (KNRK) cells ectopically expressing the substance P receptor (46). In all of these cell systems, the fluorescent ligand was targeted to a perinuclear compartment after prolonged internalization periods. However, whereas in NT1-transfected cells this juxtanuclear compartment was interpreted as belonging to the trans-Golgi network by virtue of its immunoreactivity for syntaxin-6 (44), in CHO and KNRK cells, it was found to correspond to lysosomes (45, 46). Conceivably, the fate of a metabolically protected ligand such as D-Trp8-SRIF, which was used in our experiments, may differ from that of native SRIF, in that the latter may be more readily targeted to lysosomes and degraded than the former. However, recent studies on CHO cells expressing the sst2 receptor subtype have shown iodinated native SRIF-14 to be internalized, recycled to the extracellular medium, and reinternalized several times (47), suggesting that even native peptide may be targeted to recycling compartments. Clearly, further experiments using native ligands are needed to determine the fate of SRIF internalized via the sst5 receptor subtype under physiological conditions.

The pattern of sst5 internalization, as visualized here by receptor immunofluorescence, differed sharply from that of its fluorescent ligand. At time zero, sst5 immunoreactivity was concentrated at the level of the plasma membrane as well as in a very prominent cytoplasmic pool in the core of the cell. The existence of such a pool of intracellular sst5, even after prolonged preincubation with cycloheximide, was previously reported by others in different cell lines (29) and presumably largely corresponds to trans-Golgi network/Golgi stores. After exposure to the ligand, there was very little change in the intensity of cell surface labeling. However, the intracellular cytoplasmic pool became progressively less prominent as most of the immunoreactivity accumulated at the periphery of the cell. The lack of an apparent decrease in cell surface labeling was unlike what had previously been reported for either sst2A (35) or sst3 (29, 30) receptors expressed either naturally or ectopically in other cell lines. It also differed from the confocal microscopic pattern of ligand-induced internalization reported for other G protein-coupled receptors, such as the neurokinin-1 receptor (46), the ß-adrenergic receptor (48), or the TRH receptor (49), all cases for which a significant decrease in cell surface labeling was observed in the initial stages of internalization. The question arose as to whether the preservation of cell surface receptors observed here in the case of sst5 could be attributed to receptor recycling and/or to a mobilization of receptors from intracellular stores to the cell surface.

To determine the extent to which receptor recycling contributed to the preservation of cell surface labeling, internalization assays were carried out in the presence and the absence of the recycling inhibitor monensin. In the absence of monensin, [125I]SRIF association with sst5-transfected COS-7 cells did not reach equilibrium, even at concentrations of the ligand as high as 1 µM. This lack of saturability was clearly a consequence of the internalization process, as in the presence of the endocytosis inhibitor PAO, saturation was reached. In the presence of monensin, association of [125I]SRIF with whole cells was also saturable and amounted to roughly 40% of the binding observed at equimolar concentrations of the ligand in the absence of the drug. These results demonstrate that receptor recycling accounts for part of the maintenance of cell surface receptors in the course of internalization, but that other mechanisms, such as targeting of receptors from an intracellular reserve pool to the membrane, must also be invoked.

To further investigate this idea, we carried out an immunoelectron microscopic study of sst5 after pulse-chase stimulation with SRIF. These experiments confirmed that sst5 receptors were present at the plasma membrane at all times, even after ligand exposure. In fact, they revealed that there was even an overshoot in receptor targeting to the membrane at 10 min of incubation, as reflected by the ratio between cell surface-associated and intracellular receptors, which rose from approximately 0.2 at 0 min to almost 0.9 after 10 min of incubation with the ligand. This effect was accompanied by a redistribution of receptor molecules inside the cytoplasm, which, from a peak distance of 2–3 µm from the plasma membrane at time zero, shifted to a peak distance of 0.25–0.5 µm at 10 min, suggesting a massive recruitment of reserve receptors to the plasmalemma. At 40 min, the intracellular receptor distribution had started to return to normal, as reflected by the presence of two peaks, one still close to the membrane (as seen at 10 min), but the second deeper inside the cell.

These joint recycling and recruitment mechanisms, providing for continuous availability of functional receptors at the cell surface even during massive and prolonged ligand exposure, have profound implications for receptor function, in that they might effectively protect the receptor from long term desensitization. It is interesting to recall, in this context, that the rapidly desensitizing receptor subtype sst2A (28, 45, 50, 51) acts together with sst5 to regulate GH release from the anterior pituitary (17). It may be that in cells such as these, and perhaps also in regions of the brain in which sst2A and sst5 coexist (21, 22, 26), sst5 actually provides for a prolongation of SRIF signaling after sst2A has been down-regulated.

In conclusion, the present study demonstrates that SRIF is rapidly and efficiently internalized via the sst5 receptor in a heterologous expression system. It shows that this endocytosis is mediated through a clathrin-dependent mechanism. A major finding is that in response to agonist stimulation and endocytosis, internalized sst5 receptors are rapidly recycled back to the cell surface. At the same time, spare receptors from an intracytoplasmic reserve pool are addressed to the plasma membrane. The combination of these two processes provides for the continuous presence of sst5 receptors at the cell surface and, therefore, accounts for the lack of saturability of SRIF binding to intact cells expressing sst5.


    Acknowledgments
 
We thank Dr. A.M. O’Carroll for providing us with the sst5 plasmid and Mariette Houle and Hans-Hinrich Hönck for excellent technical assistance.


    Footnotes
 
1 This work was supported by grants from the Medical Research Council of Canada (to A.B.; MT-7366) and the Deutsche Forschungsgemeinschaft (to H.-J.K.; Ha 2445/1–1). Travel between A.B.’s and J.M.’s laboratories was supported by an INSERM/FRSQ exchange program. T.S. was funded by a research fellowship from the Deutsche Forschungsgemeinschaft (Str 565/1–1). Back

Received June 16, 1999.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Epelbaum J 1986 Somatostatin in the central nervous system: physiology and pathological modifications. Prog Neurobiol 27:63–100[CrossRef][Medline]
  2. Patel YC 1992 General aspects of the biology and function of somatostatin. In: Weil C, Müller EE, Thorner MO (eds) Somatostatin. Springer Verlag, Berlin, pp 1–16
  3. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R 1973 Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77–79[Abstract/Free Full Text]
  4. Martinez V, Coy, DH, Lloyd K, Tache Y 1996 Intracerebroventricular injection of somatostatin sst5 receptor agonist inhibits gastric acid secretion in rats. Eur J Pharmacol 296:153–160[CrossRef][Medline]
  5. Fagan SP, Azizzadeh A, Moldovan S, Ray MK, Adrian TE, Ding X, Coy DH, Brunicardi FC 1998 Insulin secretion is inhibited by subtype five somatostatin receptor in the mouse. Surgery 124:254–258[Medline]
  6. Buscail L, Estève JP, Saint-Laurent N, Bertrand V, Reisine T, O’Carroll AM, Bell GI, Schally AV, Vaysse N, Susini C 1995 Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92:1580–1584[Abstract/Free Full Text]
  7. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalthoff H, Lluis, F, Vaysse N, Susini C 1996 Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 56:1823–1827[Abstract/Free Full Text]
  8. Cordelier P, Estève JP, Bousquet C, Delesque N, O’Carroll AM, Schally AV, Vaysse N, Susini C, Buscail L 1997 Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc Natl Acad Sci USA 94:9343–9348[Abstract/Free Full Text]
  9. Delesque N, Buscail L, Estève JP, Saint-Laurent N, Müller C, Weckbecker G, Bruns C, Vaysse N, Susini C 1997 sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res 57:956–962[Abstract/Free Full Text]
  10. Bruno JF, Xu Y, Song J, Berelowitz M 1992 Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proc Natl Acad Sci USA 89:11151–11155[Abstract/Free Full Text]
  11. Kluxen FW, Bruns C, Lübbert H 1992 Expression cloning of a rat brain somatostatin receptor cDNA. Proc Natl Acad Sci USA 89:4618–4622[Abstract/Free Full Text]
  12. Meyerhof W, Wulfsen I, Schönrock C, Fehr S, Richter D 1992 Molecular Cloning of a somatostatin-28 receptor and comparison of its expression pattern with that of a somatostatin-14 receptor in rat brain. Proc Natl Acad Sci USA 89:10267–10271[Abstract/Free Full Text]
  13. O’Carroll AM, Lolait SJ, König M, Mahan LC 1992 Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28. Mol Pharmacol 42:939–946[Abstract]
  14. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S 1992 Cloning and functional characterization of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA 89:251–255[Abstract/Free Full Text]
  15. Yasuda K, Rens-Domiano S, Breder CD, Law SF, Saper CB, Reisine T, Bell GI 1992 Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylcyclase. J Biol Chem 267:20422–20428[Abstract/Free Full Text]
  16. Reisine T, Bell GI 1995 Molecular properties of somatostatin receptors. Neuroscience 67:777–790[CrossRef][Medline]
  17. Shimon I, Taylor JE, Dong JZ, Bitonte R, Kim S, Morgan B, Coy DH, Culler MD, Melmed S 1997 Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 99:789–798[Medline]
  18. Bruno JF, Xu Y, Song J, Berelowitz M 1993 Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat. Endocrinology 133:2561–2567[Abstract]
  19. Raulf F, Pérez J, Hoyer D, Bruns C 1994 Differential expression of five somatostatin receptor subtypes, SSTR1–5, in the CNS and peripheral tissue. Digestion [Suppl 3] 55:46–53
  20. Viollet C, Faivre-Baumann A, Zhang J, Llorens-Cortes C, Loudes C, Kordon C, Epelbaum J 1995 Differential expression of somatostatin receptors by quantitative PCR in the rat brain. C R Acad Sci [D] (Paris) 318:851–857
  21. Dournaud P, Gu YZ, Schonbrunn A, Mazella J, Tannenbaum GS, Beaudet A 1996 Localization of the somatostatin receptor sst2A in rat brain using a specific anti-peptide antibody. J Neurosci 16:4468–4478[Abstract/Free Full Text]
  22. Schindler M, Sellers LA, Humphrey PPA, Emson PC 1997 Immunohistochemical localization of the somatostatin sst2(A) receptor in the rat brain and spinal cord. Neuroscience 76:225–240[Medline]
  23. Helboe L, Møller M, Nørregaard L, Schiødt M, Stidsen, CE 1997 Development of specific antibodies against the human somatostatin receptor subtypes sst1-sst5. Mol Brain Res 49:82–88[Medline]
  24. Helboe L, Stidsen CE, Møller M 1998 Immunohistochemical and cytochemical localization of the somatostatin receptor subtype sst1 in the somatostatinergic parvocellular neuronal system of the rat hypothalamus. J Neurosci 18:4938–4945[Abstract/Free Full Text]
  25. Hervieu G, Emson PC 1998 The localization of somatostatin receptor 1 (sst1) immunoreactivity in the rat brain using an N-terminal specific antibody. Neuroscience 85:1263–1284[CrossRef][Medline]
  26. Stroh T, Kreienkamp H-J, Beaudet A 1999 Immunohistochemical distribution of the somatostatin receptor subtype 5 in the adult rat brain: predominant expression in the basal forebrain. J Comp Neurol, 412:69–82[CrossRef][Medline]
  27. Hukovic N, Panetta R, Kumar U, Patel YC 1996 Agonist-dependent regulation of cloned human somatostatin receptor types 1–5 (hSSTR1–5): subtype selective internalization or upregulation. Endocrinology 137:4046–4049[Abstract]
  28. Nouel D, Gaudriault G, Houle M, Reisine T, Vincent J-P, Mazella J, Beaudet A 1997 Differential internalization of somatostatin in COS-7 cells transfected with sst1 and sst2 receptor subtypes: a confocal microscopic study using novel fluorescent somatostatin derivatives. Endocrinology 138:296–306[Abstract/Free Full Text]
  29. Roostermann D, Roth A, Kreienkamp H-J, Richter D, Meyerhof W 1997 Distinct agonist-mediated endocytosis of cloned rat somatostatin receptor subtypes expressed in insulinoma cells. J Neuroendocrinol 9:741–751[CrossRef][Medline]
  30. Roth A, Kreienkamp H-J, Nehring RB, Roosterman D, Meyerhof W, Richter D 1997 Endocytosis of the rat somatostatin receptors: subtype discrimination, ligand specificity, and delineation of carboxy-terminal positive and negative sequence motifs. DNA Cell Biol 16:111–119[Medline]
  31. Kreienkamp H-J, Roth A, Richter D 1998 Rat somatostatin receptor subtype 4 can be made sensitive to agonist-induced internalization by mutation of a single threonine (residue 331). DNA Cell Biol 17:869–878[Medline]
  32. Lefkowitz RJ, Pitcher J, Krüger K, Daaka Y 1998 Mechanisms of ß-adrenergic receptor desensitization and resensitization. Adv Pharmacol 42:416–420
  33. Bunnett NW, Bouvier M, De Blasi A 1998 Peptide G protein-coupled receptors meet at Erice. Trends Pharmacol Sci 19:343–346[CrossRef][Medline]
  34. Ferguson SSG, Zhang J, Barak LS, Caron MG 1998 Role of ß-arrestins in the intracellular trafficking of G-protein-coupled receptors. Adv Pharmacol 42:420–424
  35. Sarret P, Nouel D, Dal Farra C, Vincent J-P, Beaudet A, Mazella J 1999 Receptor-mediated internalization is critical for the inhibition of the expression of growth-hormone by somatostatin in the pituitary cell line AtT-20. J Biol Chem 274:19294–19300[Abstract/Free Full Text]
  36. Hunyadi L, Merelli F, Baukal AJ, Balla T, Catt KJ 1991 Agonist-induced endocytosis and signal generation in adrenal glomerulosa cells. J Biol Chem 266:2783–2788[Abstract/Free Full Text]
  37. Daaka Y, Luttrell LM, Ahn S, Della Rocca GJ, Ferguson SSG, Caron MG, Lefkowitz RJ 1998 Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. J Biol Chem 273:685–688[Abstract/Free Full Text]
  38. Ignatova EG, Belcheva MM, Bohn LM, Newman MC, Coscia CJ 1999 Requirement of receptor internalization for opioid stimulation of mitogen-activated protein kinase: biochemical and immunofluorescence confocal microscopic evidence. J Neurosci 19:56–63[Abstract/Free Full Text]
  39. Hukovic N, Panetta R, Kumar U, Rocheville M, Patel YC 1998 The cytoplasmic tail of the human somatostatin receptor type 5 is crucial for interaction with adenylyl cyclase and in mediating desensitization and internalization. J Biol Chem 273:21416–21422[Abstract/Free Full Text]
  40. Karolin J, Johansson LB-A, Strandberg L, Ny T 1994 Fluorescence and absorption spectroscopic properties of dipyrrometheneboron difluoride (BODIPY) derivatives in liquids, lipid membranes, and proteins. J Am Chem Soc 116:7801–7806[CrossRef]
  41. Koenig JA, Edwardson JM 1997 Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci 18:276–287[Medline]
  42. Raynor K, O’Carroll A-M, Kong H, Yasuda K, Mahan LC, Bell GI, Reisine T 1993 Characterization of cloned somatostatin receptors SSTR4 and SSTR5. Mol Pharmacol 44:385–392[Abstract]
  43. Hoyer D, Lübbert H, Bruns C 1994 Molecular pharmacology of somatostatin receptors. Naunyn Schmiedeberg Arch Pharmacol 350:441–453[Medline]
  44. Vandenbulcke F, Nouel D, Vincent J-P, Beaudet A 1998 Differential intracellular trafficking of neurotensin and of its receptor in cos-7 transfected cells. Society for Neuroscience Abstract 24, 1592
  45. Roettger BF, Rentsch RU, Pinon D, Holicky E, Hadac E, Larkin JM, Miller LJ 1995 Dual pathways of internalization of the cholecystokinin receptor. J Cell Biol 128:1029–1041[Abstract/Free Full Text]
  46. Grady EF, Garland AM, Gamp PD, Lovett M, Payan DG, Bunnett NW 1995 Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor. Mol Biol Cell 6:509–524[Abstract]
  47. Koenig JA, Kaur R, Dodgeon I, Edwardson JM, Humphrey PPA 1998 Fates of endocytosed somatostatin sst2 receptors and associated agonists. Biochem J 336:291–298
  48. von Zastrow M, Kobilka BK 1992 Ligand-regulated internalization and recycling of human ß2-adrenergic receptors between the plasma membrane and endosomes containing transferrin receptors. J Biol Chem 267:3530–3538[Abstract/Free Full Text]
  49. Ashworth R, Yu R, Nelson EJ, Dermer S, Gershengorn MC, Hinkle P 1995 Visualization of the thyrotropin-releasing hormone receptor and its ligand during endocytosis and recycling. Proc Natl Acad Sci USA 92:512–516[Abstract/Free Full Text]
  50. Koenig JA, Edwardson JM, Humphrey PPA 1997 Somatostatin receptors in Neuro2A neuroblastoma cells: ligand internalization. Br J Pharmacol 120:52–59[CrossRef][Medline]
  51. Beaumont V, Hepworth MB, Luty JS, Kelly E, Henderson G 1998 Somatostatin receptor desensitization in NG108–15 cells. A consequence of receptor sequestration. J Biol Chem 273:33174–33183[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
E. Peverelli, G. Mantovani, D. Calebiro, A. Doni, S. Bondioni, A. Lania, P. Beck-Peccoz, and A. Spada
The Third Intracellular Loop of the Human Somatostatin Receptor 5 Is Crucial for Arrestin Binding and Receptor Internalization after Somatostatin Stimulation
Mol. Endocrinol.,